Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Axon Enterprise Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Axon Enterprise Inc trades at $566.08 (market cap $45.60B). The key difference: Alnylam Pharmaceuticals, Inc. and Axon Enterprise Inc are close in size by market cap, and Axon Enterprise Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AXON | |
|---|---|---|
Market Cap | $39.89B | $45.60B |
Sector | Health | Technology |
52-Week High | $491.22 | $870.97 |
52-Week Low | $278.09 | $345.94 |
Enterprise Value | $38.15B | $46.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Axon trades at $565.80, down 2.78% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. The company maintains solid revenue growth, reaching $2.78 billion in 2025, though valuation ratios like P/E of 228.15 appear elevated. Positive news includes a Zacks Strong Buy upgrade and federal rulings favoring nonlethal enforcement technology.
Outlook remains positive with an 80.95% analyst buy rating and $640.33 consensus price target, suggesting 13% upside. Key risks include high valuation sensitivity and execution challenges in scaling software services. Investor sentiment is buoyed by institutional interest and strategic expansions in counter-drone capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
